Robust EM continual reassessment method in oncology dose finding
DOI10.1198/JASA.2011.AP09476zbMATH Open1229.62149OpenAlexW2041369657WikidataQ41545765 ScholiaQ41545765MaRDI QIDQ3111177FDOQ3111177
Authors: Ying Yuan, Guosheng Yin 
Publication date: 18 January 2012
Published in: Journal of the American Statistical Association (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc3286608
Recommendations
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Continual reassessment and related dose-finding designs
- A note on the robustness of the continual reassessment method
- A note on continual reassessment method
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
model selectionexpectation-maximization algorithmmissing datamaximum tolerated dosemodel averagingadaptive designlate-onset toxicity
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cited In (10)
- Biomarker-based precision dose finding for immunotherapy combined with radiotherapy
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
- Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
- Adaptive clinical trial designs for phase I cancer studies
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Application of gamma process to two-agent combinations with delayed toxicity
This page was built for publication: Robust EM continual reassessment method in oncology dose finding
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3111177)
